There are currently 6 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are .
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268
Recruiting
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the par... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/14/2025
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +160 locations
Conditions: Sickle Cell Disease
Register for Updates
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712
Recruiting
This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat. Eligible participants who enter the study will start a 96-week treatment period. At the end of the 96 weeks, participants will have an end of study visit that occurs 4 weeks later. The participants will receive etavopiv... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
06/16/2025
Locations: The Hospital for Sick Children, Toronto, Ontario +14 locations
Conditions: Sickle Cell Disease
Register for Updates
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
NCT03587272
Recruiting
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
12/19/2024
Locations: Children's National Health System, Washington, District of Columbia +6 locations
Conditions: Sickle Cell Disease
Register for Updates
Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
NCT03214354
Recruiting
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of don... Read More
Gender:
ALL
Ages:
Between 1 year and 19 years
Trial Updated:
12/05/2024
Locations: Alberta Children's Hospital, Calgary, Alberta
Conditions: Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell Aplasia
Register for Updates
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients with Sickle Cell Disease
NCT05861453
Recruiting
To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +20 locations
Conditions: Sickle Cell Disease
Register for Updates
The BENeFiTS Trial in Beta Thalassemia Intermedia
NCT04432623
Recruiting
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.The diseases are characterized by hemolytic anemia, organ damage, and early mortality without treatment. Increases in another type of (normal) hemoglobin, fetal globin (HbF), which is normally silenced in infancy, reduces anemia and morbidity. Even incremental augmentation of fetal g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: UCSF Benioff Children's Hospital at Oakland, Oakland, California +4 locations
Conditions: Beta Thalassemia Intermedia, Sickle Cell Disease
Register for Updates